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1. Introduction 
Allergic rhinitis (AR) is a symptomatic nose disorder induced after exposure to allergens via 
IgE-mediated hypersensitivity reactions, which are characterized by 4 cardinal symptoms: 
nasal obstruction, watery rhinorrhea, nasal itching and sneezing. For both children and 
adults, AR is more than just sneezing and nose itching. Complications of this disease are 
numerous and can have a significant impact, both physically and psychosocially. Major 
comorbidities in patients with AR include asthma, rhinosinusitis (RS), otitis media with 
effusion (OME), and sleep disturbance. The symptoms of AR can cause not only physical 
problems to the nose and lower airway, but also psychosocial problems including those in 
learning and cognitive processes and in missing work or school (Fig. 1). Thus, it is very 
important to understand other conditions caused by AR when managing this disorder. 
 
 
Fig. 1. Physical and psychological comorbidities of AR (Adapted from Spector, 1997) 
The ongoing efforts of physicians to identify comorbidities of AR in the fields of allergy can 
be put to practical use in caring and protecting the community from the burden of disease as 
well as saving costs and offering preventive education. Moreover, providing information to 
the patients with AR is expected to have a direct and positive effect on their well being. 
In this chapter, we will provide an overview of the comorbidities of AR that could cause 
both physical and psychosocial complications. 
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2. Physical comorbidities 
2.1 AR and asthma 
AR and asthma affect the upper and lower respiratory tract, respectively. Both are 
characterized by inflammation of the respiratory mucosa and involve similar inflammatory 
cells and mediators. Moreover AR and asthma have a considerable impact on quality of life, 
work and school productive, absenteeism, and individual and socioeconomic burden 
(Gaugris et al., 2006; Bachert et al., 2002; Bousquet et al., 2001). The socioeconomic burden 
via annual costs of treating AR and asthma, both direct costs such as hospitalization, 
medication and indirect costs such as time lost from work are substantial, and represent 
heavier burden in modern societies. 
2.1.1 Association between AR and asthma 
AR and asthma commonly coexist. Among asthmatic patients, approximately 85% also have 
AR. Conversely, up to 40% of AR patients have or will develop asthma (Bousquet et al., 
2001; Guerra et al., 2002). There are many common anatomical and pathophysiological 
features between upper and lower airway disorders, primarily in histology and 
immunology. Examples of common anatomical features include ciliated columnar epithelial 
cells, mucinous glands, vasculature, and innervation (Baraniuk, 1997). Both AR and asthma 
are chronic inflammatory diseases of the upper and lower airways and their inflammatory 
mechanisms are characterized by inflammatory infiltrates made up of eosinophils, T cells, 
and mast cells that release several mediators, chemokines and cytokines, inducing local and 
systemic IgE synthesis, and activate a systemic link via the bone marrow. 
AR has been shown to be a risk factor for asthma in children and adults (Leynaert et al., 
2000). A longitudinal, population-based study confirmed an association between AR and 
adult-onset asthma (Shaaban et al., 2008). In another study, among 1,836 college freshman, 
those with AR were significantly more likely to have asthma by the 23-year follow-up than 
those without (Settipane et al., 1994). 
In AR, one distinction is heavy vascularization of the nasal passages, which may lead to 
severe nasal obstruction. In asthma, the presence of smooth muscle from the trachea to the 
bronchioles can result in characteristic bronchoconstriction. Despite these differences, 
similarities exist. Notably, the anatomical structure and physiology of the airway mucosa 
are similar in both upper and lower airway (Bousquet et al., 2003). 
Inflammation is a central component of both conditions. In AR, the inflammatory cascade is 
initiated by allergen deposition on the nasal mucosa and comprises early-phase and often 
late-phase responses. The antigen cross-links and activates IgE receptors, resulting in the 
degranulation of mast cells and the release of several mediators of inflammation, including 
histamine, prostaglandins, leukotrienes, and proteases, leading to sneezing, itching, 
rhinorrhea and congestion symptoms of AR. In asthma, antigen cross-linking and activation 
of IgE receptors may precipitate acute airway constriction.  
AR may promote or exacerbate asthma through several physiological mechanisms that link 
2 disorders. An early study investigating the integrated airway hypothesis suggested a 
nasobronchial reflex arc as a potential mechanism linking upper and lower airway disorders 
(Kaufman et al., 1970). Based on this hypothesis, nasal allergen challenge affects bronchial 
hyperresponsiveness through a reflex arc that involves trigeminal afferents and vagal 
efferents. In addition, other mechanisms include systemic release of mediators and 
cytokines, postnasal drip resulting irritation and oral breathing caused by nasal obstruction, 
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which causes dry, cold air to penetrate into the bronchi and promote bronchial 
hyperresponsiveness (Meltzer, 2005) (Fig. 2). 
 
 
Fig. 2. Mechanisms of pathologic relationships between upper and lower airways (Adapted 
from Meltzer, 2005). 
2.1.2 Asthma evaluation in AR 
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines recommend that asthma 
patients be evaluated for AR and, conversely, that AR patients be evaluated for asthma 
(Bousquet et al., 2001). In a prospective study evaluating 375 adults with persistent 
moderate to severe AR and 115 controls, the authors concluded that patients with persistent 
moderate to severe AR without an asthma diagnosis should be evaluated for the lower 
airway with pulmonary function testing (Ciprandi et al., 2008). Similarly, ARIA 2008 
updates recommend that persistent AR patients should be evaluated for asthma (Bousquet 
et al., 2008). In our previous study, 173 AR patients were evaluated for the lower airway 
with the methacholine bronchoprovocation test and we recommend lower airway 
evaluation for the selected patients with nasal polyps, moderate to severe symptoms, and 
high blood eosinophil count (>320 cells/µL) instead of a routine lower airway evaluation 
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(Ahn et al., 2010). In another study, persistent type of rhinitis and parental history of asthma 
were significant and independent risk factors for bronchial hyperresponsiveness in AR 
children (Choi et al., 2007).  
2.1.3 Treatment of AR 
Early, active treatment of AR may be appropriate to decrease the incidence and morbidity 
associated with asthma. In a retrospective US cohort study of medical records covering 1 
year for 4,944 asthmatic patients, approximately 73% were treated for AR. Asthma-related 
events occurred more often in untreated patients than in treated patients (6.6% vs. 1.3%) 
(Crystal-Peters et al., 2002). 
Controlling nasal symptoms with intranasal steroids improves asthma symptoms and 
nonspecific bronchial hyperresponsiveness (Watson et al., 1993). The authors reported that 
bronchial hyperresponsiveness to methacholine was significantly reduced in patients with 
perennial AR and asthma following treatment with intranasal steroids but not following 
intranasal placebo. More importantly, they also performed a radiolabeled deposition study 
of intranasal steroid administration and found that less than 2% was deposited in the chest 
area. These results suggest that treatment of inflammation in the upper airways indirectly 
improves asthma symptoms and decreases bronchial hyperresponsiveness, which is not a 
direct effect of the intranasally administered corticosteroid on the lower airways (Watson et 
al., 1993).  
A 3-year retrospective cohort study conducted in 14 US centers evaluated whether treatment 
with intranasal corticosteroid (INS) in patients of 5 years or older with asthma was 
associated with a reduced risk of emergency room visits for asthma (Adams et al., 2002). 
Treatment of nasal conditions, particularly with INSs, appeared to prevent asthma 
exacerbations leading to emergency room visits.  
2.2 AR and RS 
AR and RS are increasingly being regarded as interrelated and part of a spectrum of upper 
airway inflammatory disease. AR also may be a contributing factor in 25% to 30% of patients 
with acute maxillary sinusitis and in as many as 60% to 80% of patients with chronic 
sinusitis (Spector, 1997). At the least, AR is associated with and probably a predisposing 
factor in the development of RS (Slavin, 1998). Both conditions are characterized by an 
inflammatory response leading to an altered milieu within the nose and paranasal sinuses, 
thus rendering normal host defenses weakened and susceptible to further inflammatory 
insult. 
However, the role of allergy in the pathogenesis of RS has been under debate and 
controversy over the past several years.  
2.2.1 Association between AR and RS 
RS is an inflammation of the nose and paranasal sinuses, attributed to many potential 
factors. The term “rhinosinusitis” rather than “sinusitis” reflects more accurately close 
anatomical and pathophysiological relationship between rhinitis and chronic sinusitis, 
which are commonly comorbid. The typical pathophysiological scheme leading to the 
development of RS starts with some inciting agents (viral, bacterial, fungal, allergen) or 
predisposing factor (anatomical, immunological) leading to generalized mucosal edema and 
inflammation. In the development of RS, mucosal inflammation leads to ciliary dysfunction 
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and mucus stasis, as well as edema of the sinus ostia. The stasis of secretions within the 
sinuses serves as a nidus for bacterial colonization and growth. These events coupled with 
the impairment of host defenses as a result of the inflammatory mediators released in 
response to the inciting agent, create a cycle of sustained inflammation that can chronically 
damage the nasal and paranasal sinus linings (Ahmad and Zacharek, 2008; Gwaltney et al., 
1995) (Fig. 3).  
 
 
Fig. 3. Sinus cycle leading to RS (Adapted from Ahmad and Zacharek, 2008) 
Adult chronic RS was defined as a group of disorders characterized by inflammation of the 
mucosa of the nose and paranasal sinuses of at least 12 weeks duration. In the past, chronic 
RS was characterized as a disease process caused by an anatomical obstruction of the sinus 
ostia, specifically ostiomeatal complex occlusion. The factors leading to this obstruction 
included viral infection aided by anatomical factors, leading to mucosal inflammation and 
edema, with thickening of mucus secretions and secondary bacterial infection. It has become 
clear that the pathogenic mechanisms are more complex than would be explained by a 
simple model and that there are other chronic inflammatory processes that contribute to the 
development of chronic RS. However, the exact mechanism by which allergy predisposes to 
the development of chronic RS has not been fully elucidated. 
According to another model of the pathogenesis of RS, chronic RS is characterized by 
basement membrane thickening, subepithelial fibrosis and edema, goblet cell hyperplasia, 
and persistent inflammation (Christodoulopoulos et al., 2000). Like in asthma, remodeling of 
the mucosa occurs in response to this chronic and progressive inflammation. This model of 
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pathogenesis also supports the notion of a unified airway with similar histopathological 
changes and immunological mechanism occurring as a result of inflammatory insult. 
In a 1989 study, skin testing in 2 groups of young adults, one with acute maxillary sinusitis, 
and a matched group without sinusitis, revealed that the prevalence of positive allergen 
testing was greater in the group with RS (45% vs. 33%) (Savolainen, 1989). The author thus 
concluded that allergy did play a role in the development of acute RS, and that it was more 
common among atopic individuals. In another study, positive inhalant allergy testing was 
present in over 50% of the 120 patients undergoing endoscopic sinus surgery, which led him 
to conclude that allergy may be a predisposing cause of chronic sinusitis (Kennedy, 1992). 
The contribution of allergy in the pathophysiology of both acute and chronic RS has been 
supported by studies examining the role of the ethmoid sinuses in terms of immunological, 
histopathological and postsurgical changes. The ethmoid mucosa affected by RS 
demonstrates an increased CD4/CD8 ratio and increase in the number of eosinophils and 
mast cells as well as extracellular matrix deposition, basement membrane disruption, and 
denudation of the epithelium (Christodoulopoulos et al., 2000). These findings are similar to 
the effect of allergy on other parts of the respiratory tract. In another study attempting to 
correlate tissue histopathology in chronic RS with immune mechanisms in allergic disease, 
the conclusions were that the proposed method for quantifying tissue eosinophilia in sinus 
mucosa was reliable and valid and that a relatively strong correlation existed between CT 
scan stage and tissue eosinophilia in chronic RS (Bhattacharyya et al., 2001).  
Several studies examining the relationship between allergen exposure or provocation and 
RS exacerbation have also suggested a common mechanism in AR and RS (Pelikan and 
Pelikan-Filipek, 1990; Conner et al., 1989; Slavin, 1998). The investigators demonstrated an 
increase in metabolic activity of the maxillary sinus mucosa in chronic RS patients during 
ragweed season, using single-photon emission CT scanning (Slavin, 1998).  
Evidence of a common pathophysiological mechanism between AR and RS is convincing. 
Although a clear causal mechanism leading from AR to the development of RS remains to 
be elucidated, an increasing number of studies have found the possibility and evidence of 
this link. 
2.3 AR and OME 
OME is one of the most commonly encountered diseases in children, affecting 
approximately 90% of children at some time before school age (Tos, 1984). OME is 
characterized by an accumulation of fluid in the middle ear behind an intact tympanic 
membrane in the absence of signs and symptoms of acute infection. If we look at the natural 
history of OME, many cases are self-limited and resolve spontaneously (Williamson et al., 
1994). But, OME is the most frequent cause of hearing loss in children (Thomas et al., 2006; 
Shekelle et al., 2002). 
An epidemiologic link between OME and AR has been demonstrated in many trials (Alles et 
al., 2001; Tomonaga et al., 1988). Prevalence of AR among patients with chronic or recurrent 
OME is higher than that seen in the same age group in the general population. 
2.3.1 Pathophysiology of OME and AR 
The etiology of OME is multifactorial. It may be related to bacterial infection, poor clearance 
due to Eustachian tube (E-tube) dysfunction, local inflammatory reactions and possibly 
atopy (Thomas et al., 2006; Luong and Roland, 2008). 
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Data from several animal studies have suggested a link between nasal allergic inflammation 
and E-tube dysfunction. For example, an intranasal pollen antigen challenge significantly 
compromised E-tube function in 23 passively sensitized juvenile rhesus monkeys (Doyle et 
al., 1984). A nasal allergen challenge in rats resulted in E-tube inflammation, negative 
pressure and hindrance of mucociliary clearance (Ebert et al., 2007). Another previous study 
showed negative middle ear pressure following nasal allergen challenge in subjects with AR 
and hypothesized the involvement of both immunological and mechanical mechanisms 
(O'Connor et al., 1984). E-tube dysfunction developed during allergy season in 60% of 
children with seasonal AR and correlated with AR symptom severity (Osur et al., 1989).  
Because the E-tube lining is contiguous with the nasopharynx, allergic disorders such as AR 
may cause inflammation and swelling in this region resulting in E-tube obstruction in the 
same manner as in the nasal mucosa (Alles et al., 2001; Luong and Roland, 2008; Fireman, 
1988) (Fig. 4). Furthermore, it has been found that a reduction in the size of the lumen in an 
inflamed E-tube could impede mucociliary function, thus delaying clearance of acute 
infective middle ear effusion, leading to recurrent OME (Alles et al., 2001). 
Several studies analyzing middle ear mucosa and effusions in atopic patients with OME 
have demonstrated that the composition of the inflammatory substrate in acute otitis media 
is similar to the type I late-phase allergic response seen in other areas of the respiratory tract, 
such as in AR, chronic RS, and asthma (Nguyen et al., 2004; Sobol et al., 2002; Hurst, 1996). 
The middle ear effusions of atopic patients with OME showed significantly higher levels of 
eosinophils, T lymphocytes, and IL-4 mRNA+ cells (p<0.01) and significantly lower levels of 
neutrophils and IFN-γ mRNA+ cells (p<0.01) compared to non-atopic patients with OME 
(Nguyen et al., 2004). Similarly, in another study, a higher percentage of eosinophils and T 
lymphocytes, and a higher percentage of cells expressing IL-4 and IL-5 were found among 
atopic patients with OME (Sobol et al., 2002). 
 
 
Fig. 4. Schematic diagram showing anatomical relationship of E-tube between the 
nasopharynx and middle ear (Adapted from Fireman, 1988) 
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2.3.2 Treatment of OME 
Because of the pathophysiological associations of AR with OME, treatments focusing on 
allergic inflammation may be helpful in the management of OME (Caffarelli et al., 1998; 
Fireman, 1988).  
A meta-analysis of 16 randomized controlled trials demonstrated no significant benefit from 
antihistamines, decongestants, or combined antihistamines and decongestants versus 
placebo for treatment of OME (Griffin et al., 2006). However, in a meta-analysis of 6 
randomized clinical trials, oral steroids administered for 7-14 days increased the rate of 
complete effusion resolution versus no steroid (Rosenfeld et al., 1991). A Cochrane database 
review yielded very similar results, demonstrating a quicker resolution of OME in the short 
term (≤2 wk) with oral steroids alone or in combination with antibiotics (Thomas et al., 
2006). However, there are likely to be safety concerns surrounding oral corticosteroids, such 
as behavioral changes, increased appetite, weight gain, and adrenal and growth 
suppression. On the contrary, INS has limited systemic absorption, these drugs offer safety 
advantages over oral corticosteroids and would be expected to exert their anti-inflammatory 
effects more locally in the nose, nasopharynx, and E-tube (Tracy et al., 1998). In this study, 
the authors compared the effects of prophylactic antibiotic alone or in combination with 
either intranasal beclomethasone or placebo on middle ear pressure, otoscopic examination, 
and symptom scores in 61 children with persistent middle ear effusion greater than 3 
months. Subjects with the beclomethasone plus antibiotic group improved more rapidly in 
middle ear pressure and otoscopic examination than those with the antibiotic alone or 
placebo groups during the initial 8 wk. At 12 wk, only the combination treatment showed 
significant improvement in bilateral ear pressures. In addition, symptom resolution was 
significantly greater at 12 wk with antibiotic plus beclomethasone group than with the 
antibiotic alone group. However, there were no differences in outcomes between atopic and 
nonatopic subjects (Tracy et al., 1998). In another previous study, patients with OME treated 
with mometasone furoate nasal spray experienced significantly higher rates of resolution of 
OME at 6 wk compared with untreated controls (42.2% vs. 14.5%; p<0.001) (Cengel and 
Akyol, 2006). 
In conclusion, atopic status should be evaluated in recurrent or chronic OME patients who 
had no response to antibiotic therapy and INS could be used as an adjunct to treatment of 
OME patients with AR. However, further studies are needed to elucidate whether atopic 
status or rhinitis itself may influence the development of OME. 
2.4 AR and sleep disturbance 
The effect of AR on sleep can impair a patient’s quality of life (Canonica et al., 2007; Schatz, 
2007). A nationwide controlled cross-sectional study showed that patients with AR have 
more difficulties in falling asleep, take more sleeping drugs, suffer from nocturnal 
awakenings, and feel that they do not get sufficient sleep when compared to healthy 
controls (Leger et al., 2006). Children with AR can experience micro-arousal during their 
sleep and irregular breathing. 
A prospective study of 39 children with habitual snoring revealed that 14 subjects (36%) 
showed sensitivity to allergens (McColley et al., 1997), which is higher than expected for the 
general pediatric population. Based on subjective criteria, sleep apnea syndrome has also 
been found to be more prevalent in AR than in controls (Leger et al., 2006). The reasons for 
poor sleep in AR are not clearly understood, but may be related, at least in part, to nasal 
congestion (Meltzer, 2004). Several studies have shown the relationships between AR and 
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nasal obstruction and abnormal breathing during sleep, snoring and sleep apnea (Scharf and 
Cohen, 1998; Young et al., 1997).  
The impact of the severity of rhinitis on quality of life including sleep, daily activities, and 
work performance was shown to be stronger than the duration of rhinitis (Bousquet et al., 
2006). Another study showed that the severity of rhinitis, but not its frequency, was significant 
factors for severe insomnia, hypersomnia, respiratory arrest, apnea, sleepiness, and regular use 
of sedatives (Leger et al., 2006). Recently, we are conducting multi-center cohort study on the 
complication of rhinitis in Korean children. All patients were classified into 4 categories 
(intermittent mild, intermittent moderate to severe, persistent mild and persistent moderate to 
severe) using ARIA classification, and Korean version of Obstructive Sleep Apnea 18 (KOSA-
18) questionnaire were performed. High KOSA-18 scores mean more sleep disturbance. In our 
cohort study, the preliminary results (n=999) showed that sleep disturbance was more 
frequent according to the ARIA classification (Fig. 5) and there were no differences between 
atopic and nonatopic patients (48.7±17.5 vs. 51.1±19.7, p=0.120) (unpublished data). 
In these groups, after the treatment of rhinitis, KOSA-18 scores at 6 months were lower than 
those of baseline; sleep disturbance were improved after the 6-month follow-up (Fig. 6). 
AR appears to increase the risk of obstructive sleep apnea syndrome (OSAS) in children. 
Adequate treatment of AR can reduce the severity of OSAS and prevent the emergence of an 
elongated face, which predisposes patients to OSAS. It may also reduce the severity of 
coexisting OSAS. 
3. Psychosocial comorbidities 
3.1 AR and cognitive disorder 
AR leads to psychosocial complications such as cognitive impairment and learning 
problems as well as physical complications. Young people, with and without treatment, 
were given the task, during the ongoing pollen season, to learn about agriculture in desert 
environments. The results showed that individuals receiving placebo or sedative 
antihistamines performed significantly worse than healthy controls (Vuurman et al., 1993). 
In another study, patients allergic to ragweed have impaired cognitive learning during the 
pollen season and some also had memory impairment (Marshall et al., 2000). It was also 
shown that patients with AR symptoms take a longer time to make decisions and have a 
slower psychomotor rate than healthy control subjects. 
However, it is under debate whether AR itself does or does not lead to learning problems 
among allergic students. Resultant symptoms, such as sleep deprivation and general 
malaise can affect concentration and learning. Consequently, this theory argues that 
cognitive difficulties are a secondary result of sleep problems. 
The consequences of AR effect on learning and other cognitive functions in relation to 
school performance have been established. A case–control study was conducted on 1,834 
students sitting for the national examinations in mathematics, English and science (Walker 
et al., 2007). Those who had allergic symptoms during the examination period had a 40% 
higher risk of achieving lower grades than students who did not have symptoms.  
Children with AR may fall behind in classes. Sniffling, rubbing and blowing the nose are 
more common among children with AR than those without. These behaviors make children 
self-conscious and peers may be annoyed by them, leading to teasing and a further increase 
in their stress levels (Meltzer, 2001) and may cause behavioral disorders. Thus, adequate 
treatment of AR should be needed, especially in school children. 
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(b) AR/NAR patients 
Fig. 5. Mean differences of KOSA-18 scores according to ARIA classification among (a) total 
patients and (b) allergic rhinitis (AR)/non allergic rhinitis (NAR) patients. All the data 
showed statistical significances (p<0.001, adjusted to age). Group A: intermittent mild, 
Group B: intermittent moderate to severe, Group C: persistent mild, Group D: persistent 
moderate to severe. □: AR patients, ■: NAR patients 
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(a) KOSA-18 scores changes between AR/NAR patients 
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(b) KOSA-18 scores changes according to ARIA classification 
 
 
 
 
Fig. 6. Mean differences of KOSA-18 scores after the treatment of rhinitis (a) between 
AR/NAR patients and (b) according to ARIA classification. Group A: intermittent mild, 
Group B: intermittent moderate to severe, Group C: persistent mild, Group D: persistent 
moderate to severe. 
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3.2 AR and missing school or work 
AR has considerable negative effects on both school-aged children and adult workers. 
Especially in school-aged children, it can not only affect sleep and cognitive function, but 
also cause school absenteeism and presenteeism. Untreated AR in childhood could cause 
sleep disturbances and daytime sleepiness, absenteeism and presenteeism (inattention, 
distraction, lack of concentration), irritability and mood disorders (Jauregui et al., 2009). In 
terms of adult workers, a previous study in the US evaluated economic impact of workplace 
productivity losses due to AR (Lamb et al., 2006). A total of 8,267 US employees at 47 
employer locations volunteered to participate in health/wellness screenings. AR was the 
most prevalent; 55% of employees reported AR symptoms for an average of 52.5 days, were 
absent 3.6 days per year. The mean total productivity losses (absenteeism+presenteeism) 
were 593 US dollars for AR, 518 dollars for high stress, 277 dollars for migraine, 273 dollars 
for depression, 269 dollars for arthritis/rheumatism, 248 dollars for anxiety disorder, 181 
dollars for respiratory infections, 105 dollars for hypertension, 95 dollars for diabetes, 85 
dollars for asthma, and 40 dollars for coronary heart disease. Thus, the authors suggested 
that allergies are major contributors to the total cost of health-related absenteeism and 
presenteeism. 
4. Conclusion 
AR has a considerable effect on one’s quality of life and can have significant consequences if 
left untreated. The consequences are more far-reaching than expected. Because all the 
possible comorbidities of AR have significant consequences to the community, it is fair to 
say that physicians and patients should pay close attention to prevent the occurrence of 
comorbidities. Furthermore, the adequate treatment of AR could prevent physical and 
psychosocial complications. 
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